Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial

EBioMedicine(2022)10.1016/j.ebiom.2022.104375Source: DataRank Database

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial is a research paper published in EBioMedicine (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 3.67)OA: goldTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Megan Birkhold ORCID,Mara Short ORCID,Timothy R. Wilson ORCID,Claudio Meneses,Joshua R. Lacsina ORCID

Live enrichment

PubMed:36436281 PMC:PMC9700263 OpenAlex:https://openalex.org/W4310370480

Innovate UK

Grant: 971556

Vaccine against mosquito-borne diseases

National Institute of Allergy and Infectious Diseases

Grant: 1K23AI155838-01A1

Serological markers of natural immunity to Plasmodium falciparum infection

National Cancer Institute

Grant: 75N91019D00024

NIAID NIH HHS

Grant: K23 AI155838

NIAID NIH HHS

Grant: T32 AI007524

National Institute for Health Research (NIHR)

Georgetown University

U.S. Department of Health and Human Services

National Institutes of Health

Samsung Biomedical Research Institute

School of Medicine, University of Maryland

FWCI

3.67

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.thelancet.com/article/S2352396422005576/pdf

publisherhttp://www.thelancet.com/article/S2352396422005576/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2352396422005576?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352396422005576?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ebiom.2022.104375

Fields of Study

Mosquito-borne diseases and controlInvertebrate Immune Response MechanismsBiological Research and Disease Studies03 medical and health sciences0302 clinical medicineAdolescentAdultAnimalsHumansMiddle AgedYoung AdultCulicidaeDouble-Blind MethodVaccinationVaccines, SubunitArbovirus InfectionsSalivary Proteins and Peptides

MeSH Terms

AdolescentAdultAnimalsArbovirus InfectionsDouble-Blind MethodHumansMiddle AgedCulicidaeSalivary Proteins and PeptidesVaccinationVaccines, SubunitYoung Adult

Keywords

MedicinePlaceboImmunogenicityAdverse effectVaccinationRandomized controlled trialSalivaInternal medicineImmunologyAntibodyPathologyMosquito-borne DiseasesVector-borne VirusesMosquito-Borne Disease VaccineAdultAdolescentArticlesMiddle AgedArbovirus InfectionsYoung AdultCulicidaeDouble-Blind MethodVaccines, SubunitAnimalsHumansSalivary Proteins and Peptides

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial

FAIR Checklist

Authors (15)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)